Bristol-Myers Squibb Co. (BMY)
Common Stock Valuation Ratios (Price Multiples)
Quarterly Data
Beginner level
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
Bristol-Myers Squibb Co., historical price multiples (quarterly data)
Based on: 10-K (filing date: 2020-02-24), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28).
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Bristol-Myers Squibb Co.’s P/E ratio increased from Q2 2019 to Q3 2019 and from Q3 2019 to Q4 2019. |
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Bristol-Myers Squibb Co.’s P/OP ratio increased from Q2 2019 to Q3 2019 and from Q3 2019 to Q4 2019. |
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Bristol-Myers Squibb Co.’s P/S ratio increased from Q2 2019 to Q3 2019 and from Q3 2019 to Q4 2019. |
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. | Bristol-Myers Squibb Co.’s P/BV ratio increased from Q2 2019 to Q3 2019 but then decreased significantly from Q3 2019 to Q4 2019. |
Price to Earnings (P/E)
Bristol-Myers Squibb Co., historical P/E calculation (quarterly data)
| Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 2,257,510,796 | 1,629,284,798 | 1,635,766,530 | 1,635,705,782 | 1,632,675,877 | 1,632,198,774 | 1,631,876,909 | 1,634,538,458 | 1,632,582,502 | 1,636,699,696 | 1,639,926,446 | 1,647,434,458 | 1,672,715,340 | 1,671,229,946 | 1,670,858,535 | 1,669,307,273 | 1,669,459,090 | 1,668,286,317 | 1,667,502,766 | 1,666,974,545 | ||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||
| Net earnings (loss) attributable to BMS (in millions) | (1,056) | 1,353 | 1,432 | 1,710 | 1,160 | 1,901 | 373 | 1,486 | (2,328) | 845 | 916 | 1,574 | 894 | 1,202 | 1,166 | 1,195 | (197) | 706 | (130) | 1,186 | ||||||
| Earnings per share (EPS)2 | 1.52 | 3.47 | 3.79 | 3.14 | 3.01 | 0.88 | 0.23 | 0.56 | 0.62 | 2.58 | 2.80 | 2.94 | 2.66 | 2.01 | 1.72 | 0.94 | 0.94 | 0.00 | 0.00 | 0.00 | ||||||
| Share price1, 3 | 63.97 | 57.37 | 45.40 | 45.64 | 50.65 | 49.21 | 57.92 | 52.04 | 63.87 | 60.95 | 54.24 | 55.67 | 54.78 | 51.96 | 74.66 | 72.26 | 60.20 | 66.80 | 68.24 | 64.54 | ||||||
| Valuation Ratio | ||||||||||||||||||||||||||
| P/E ratio4 | 41.99 | 16.53 | 11.97 | 14.51 | 16.81 | 56.09 | 251.38 | 92.56 | 103.55 | 23.59 | 19.40 | 18.96 | 20.56 | 25.80 | 43.47 | 76.64 | 64.22 | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| P/E Ratio, Competitors5 | ||||||||||||||||||||||||||
| Abbott Laboratories | 41.83 | 44.92 | 53.17 | 52.98 | 56.47 | 136.66 | 122.73 | 213.07 | 220.29 | 45.00 | 73.04 | 50.48 | 55.16 | 41.28 | 29.01 | 22.87 | 12.83 | — | — | — | ||||||
| AbbVie Inc. | 17.82 | 37.29 | 23.42 | 21.71 | 20.60 | 17.29 | 22.09 | 24.91 | 35.47 | 22.56 | 17.16 | 16.90 | 16.54 | 15.75 | 18.94 | 18.46 | 17.01 | — | — | — | ||||||
| Allergan PLC | — | — | — | — | — | 24.13 | — | — | — | — | 6.83 | 6.75 | 5.60 | 5.20 | 23.71 | 20.21 | 31.94 | — | — | — | ||||||
| Amgen Inc. | 17.07 | 15.53 | 14.06 | 13.30 | 14.01 | 55.79 | 52.69 | 52.13 | 64.06 | 15.67 | 15.70 | 15.16 | 16.03 | 14.24 | 17.32 | 16.55 | 15.95 | — | — | — | ||||||
| Biogen Inc. | 9.97 | 9.43 | 8.40 | 9.32 | 14.79 | 19.99 | 25.30 | 18.66 | 28.83 | 19.16 | 18.17 | 17.49 | 15.41 | 16.60 | 16.21 | 16.57 | 16.67 | — | — | — | ||||||
| Eli Lilly & Co. | 16.19 | 13.31 | 13.84 | 18.38 | 39.13 | 249.24 | — | 79.88 | — | 41.51 | 37.39 | 41.29 | 32.39 | 33.66 | 37.12 | 35.95 | 33.35 | — | — | — | ||||||
| Gilead Sciences Inc. | 16.45 | 30.72 | 13.61 | 14.26 | 15.26 | 57.34 | 45.72 | 24.66 | 22.75 | 8.24 | 7.85 | 6.92 | 6.83 | 6.47 | 6.49 | 6.50 | 6.75 | — | — | — | ||||||
| Johnson & Johnson | 25.99 | 24.03 | 21.50 | 25.68 | 23.74 | 243.48 | 256.64 | 271.47 | 268.10 | 23.75 | 21.91 | 20.12 | 20.08 | 19.64 | 22.55 | 20.29 | 18.80 | — | — | — | ||||||
| Merck & Co. Inc. | 20.60 | 22.67 | 23.07 | 23.97 | 33.46 | 56.97 | 132.14 | 96.71 | 61.63 | 53.20 | 33.41 | 39.83 | 46.14 | 30.16 | 33.87 | 32.46 | 31.64 | — | — | — | ||||||
| Pfizer Inc. | 11.63 | 12.60 | 16.12 | 19.69 | 21.58 | 10.64 | 10.66 | 9.43 | 9.99 | 21.39 | 23.88 | 27.02 | 28.10 | 32.43 | 30.28 | 26.41 | 26.37 | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | 19.86 | 17.03 | 15.94 | 14.56 | 18.17 | 21.53 | 26.96 | 22.09 | 28.99 | 34.90 | 43.35 | 47.93 | 42.64 | 45.15 | 61.42 | 53.53 | 60.50 | — | — | — | ||||||
| Vertex Pharmaceuticals Inc. | 52.90 | 23.44 | 20.80 | 20.51 | 22.59 | 65.41 | 108.21 | 175.96 | 155.08 | 193.19 | 149.56 | 166.15 | — | — | — | — | — | — | — | — | ||||||
| Zoetis Inc. | 45.89 | 39.46 | 42.08 | 35.57 | 28.68 | 38.90 | 39.51 | 39.53 | 44.09 | 35.00 | 33.42 | 33.79 | 31.63 | 35.08 | 39.58 | 62.14 | 62.14 | — | — | — | ||||||
Based on: 10-K (filing date: 2020-02-24), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28).
1 Data adjusted for splits and stock dividends.
2 Q4 2019 Calculation
EPS
= (Net earnings (loss) attributable to BMSQ4 2019
+ Net earnings (loss) attributable to BMSQ3 2019
+ Net earnings (loss) attributable to BMSQ2 2019
+ Net earnings (loss) attributable to BMSQ1 2019)
÷ No. shares of common stock outstanding
= (-1,056,000,000 + 1,353,000,000 + 1,432,000,000 + 1,710,000,000)
÷ 2,257,510,796 = 1.52
3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Quarterly or Annual Report.
4 Q4 2019 Calculation
P/E ratio = Share price ÷ EPS
= 63.97 ÷ 1.52 = 41.99
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Bristol-Myers Squibb Co.’s P/E ratio increased from Q2 2019 to Q3 2019 and from Q3 2019 to Q4 2019. |
Price to Operating Profit (P/OP)
Bristol-Myers Squibb Co., historical P/OP calculation (quarterly data)
| Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 2,257,510,796 | 1,629,284,798 | 1,635,766,530 | 1,635,705,782 | 1,632,675,877 | 1,632,198,774 | 1,631,876,909 | 1,634,538,458 | 1,632,582,502 | 1,636,699,696 | 1,639,926,446 | 1,647,434,458 | 1,672,715,340 | 1,671,229,946 | 1,670,858,535 | 1,669,307,273 | 1,669,459,090 | 1,668,286,317 | 1,667,502,766 | 1,666,974,545 | ||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||
| Operating income (in millions) | 557 | 1,760 | 1,877 | 1,719 | 1,567 | 1,659 | 513 | 1,379 | 556 | 992 | 756 | 1,308 | 999 | 1,335 | 1,161 | 1,135 | (82) | 664 | 159 | 1,149 | ||||||
| Operating profit per share2 | 2.62 | 4.25 | 4.17 | 3.34 | 3.13 | 2.52 | 2.11 | 2.25 | 2.21 | 2.48 | 2.68 | 2.92 | 2.77 | 2.12 | 1.72 | 1.12 | 1.13 | 0.00 | 0.00 | 0.00 | ||||||
| Share price1, 3 | 63.97 | 57.37 | 45.40 | 45.64 | 50.65 | 49.21 | 57.92 | 52.04 | 63.87 | 60.95 | 54.24 | 55.67 | 54.78 | 51.96 | 74.66 | 72.26 | 60.20 | 66.80 | 68.24 | 64.54 | ||||||
| Valuation Ratio | ||||||||||||||||||||||||||
| P/OP ratio4 | 24.42 | 13.50 | 10.89 | 13.68 | 16.16 | 19.56 | 27.48 | 23.10 | 28.87 | 24.60 | 20.23 | 19.09 | 19.79 | 24.47 | 43.34 | 64.30 | 53.18 | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | ||||||||||||||||||||||||||
| Abbott Laboratories | 34.03 | 34.32 | 37.50 | 36.74 | 36.64 | 38.12 | 38.00 | 39.99 | 60.88 | 47.72 | 41.32 | 30.85 | 24.25 | 18.51 | 23.04 | 20.13 | 19.80 | — | — | — | ||||||
| AbbVie Inc. | 10.82 | 18.43 | 13.53 | 17.93 | 18.35 | 12.32 | 14.01 | 15.78 | 19.63 | 14.77 | 11.57 | 11.19 | 10.49 | 10.48 | 12.51 | 12.44 | 11.61 | — | — | — | ||||||
| Allergan PLC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Amgen Inc. | 13.84 | 12.52 | 11.35 | 10.73 | 11.46 | 12.13 | 12.16 | 11.45 | 12.71 | 12.55 | 12.46 | 11.99 | 12.64 | 11.56 | 14.06 | 13.50 | 13.07 | — | — | — | ||||||
| Biogen Inc. | 8.34 | 7.58 | 6.74 | 7.43 | 11.13 | 10.78 | 12.80 | 9.45 | 13.70 | 14.01 | 13.19 | 12.69 | 11.08 | 11.87 | 11.51 | 11.89 | 12.09 | — | — | — | ||||||
| Eli Lilly & Co. | 27.08 | 23.37 | 23.99 | 38.43 | 33.99 | 37.45 | 47.62 | 25.86 | 39.61 | 33.07 | 29.23 | 32.37 | 25.63 | 27.59 | 30.51 | 28.95 | 29.86 | — | — | — | ||||||
| Gilead Sciences Inc. | 20.66 | 19.07 | 9.61 | 10.14 | 10.15 | 9.74 | 9.58 | 6.83 | 7.45 | 6.02 | 5.82 | 5.22 | 5.23 | 5.08 | 5.20 | 5.25 | 5.50 | — | — | — | ||||||
| Johnson & Johnson | 19.83 | 17.23 | 19.08 | 20.36 | 18.34 | 20.42 | 18.93 | 18.18 | 18.94 | 18.71 | 17.29 | 15.95 | 16.09 | 16.59 | 18.63 | 17.98 | 16.50 | — | — | — | ||||||
| Merck & Co. Inc. | 17.47 | 17.97 | 18.21 | 19.17 | 25.08 | 25.60 | 34.95 | 27.63 | 22.58 | 38.37 | 25.21 | 30.01 | 33.62 | 21.16 | 24.34 | 20.90 | 20.29 | — | — | — | ||||||
| Pfizer Inc. | 14.36 | 14.64 | 13.82 | 15.62 | 17.19 | 18.14 | 17.36 | 15.05 | 15.62 | 16.20 | 16.11 | 16.34 | 16.88 | 16.63 | 16.98 | 15.88 | 15.52 | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | 19.01 | 16.21 | 15.41 | 14.44 | 17.53 | 16.43 | 18.75 | 14.23 | 16.71 | 23.63 | 29.60 | 32.24 | 28.70 | 29.64 | 36.67 | 30.59 | 30.74 | — | — | — | ||||||
| Vertex Pharmaceuticals Inc. | 51.98 | 64.96 | 52.36 | 56.45 | 74.57 | 66.84 | 442.93 | — | 331.55 | 1,018.05 | 112.83 | 99.84 | 2,143.58 | — | — | — | — | — | — | — | ||||||
| Zoetis Inc. | 35.00 | 30.23 | 32.11 | 27.78 | 22.59 | 23.98 | 23.28 | 21.51 | 22.33 | 21.75 | 20.64 | 20.42 | 18.65 | 18.87 | 20.90 | 28.06 | 28.09 | — | — | — | ||||||
Based on: 10-K (filing date: 2020-02-24), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28).
1 Data adjusted for splits and stock dividends.
2 Q4 2019 Calculation
Operating profit per share
= (Operating incomeQ4 2019
+ Operating incomeQ3 2019
+ Operating incomeQ2 2019
+ Operating incomeQ1 2019)
÷ No. shares of common stock outstanding
= (557,000,000 + 1,760,000,000 + 1,877,000,000 + 1,719,000,000)
÷ 2,257,510,796 = 2.62
3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Quarterly or Annual Report.
4 Q4 2019 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 63.97 ÷ 2.62 = 24.42
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Bristol-Myers Squibb Co.’s P/OP ratio increased from Q2 2019 to Q3 2019 and from Q3 2019 to Q4 2019. |
Price to Sales (P/S)
Bristol-Myers Squibb Co., historical P/S calculation (quarterly data)
| Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 2,257,510,796 | 1,629,284,798 | 1,635,766,530 | 1,635,705,782 | 1,632,675,877 | 1,632,198,774 | 1,631,876,909 | 1,634,538,458 | 1,632,582,502 | 1,636,699,696 | 1,639,926,446 | 1,647,434,458 | 1,672,715,340 | 1,671,229,946 | 1,670,858,535 | 1,669,307,273 | 1,669,459,090 | 1,668,286,317 | 1,667,502,766 | 1,666,974,545 | ||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||
| Revenues (in millions) | 7,945 | 6,007 | 6,273 | 5,920 | 5,973 | 5,691 | 5,704 | 5,193 | 5,449 | 5,254 | 5,144 | 4,929 | 5,243 | 4,922 | 4,871 | 4,391 | 4,287 | 4,069 | 4,163 | 4,041 | ||||||
| Sales per share2 | 11.58 | 14.84 | 14.58 | 14.24 | 13.82 | 13.50 | 13.24 | 12.87 | 12.73 | 12.57 | 12.34 | 12.12 | 11.61 | 11.05 | 10.54 | 10.13 | 9.92 | 0.00 | 0.00 | 0.00 | ||||||
| Share price1, 3 | 63.97 | 57.37 | 45.40 | 45.64 | 50.65 | 49.21 | 57.92 | 52.04 | 63.87 | 60.95 | 54.24 | 55.67 | 54.78 | 51.96 | 74.66 | 72.26 | 60.20 | 66.80 | 68.24 | 64.54 | ||||||
| Valuation Ratio | ||||||||||||||||||||||||||
| P/S ratio4 | 5.52 | 3.87 | 3.11 | 3.21 | 3.67 | 3.64 | 4.38 | 4.04 | 5.02 | 4.85 | 4.40 | 4.59 | 4.72 | 4.70 | 7.08 | 7.13 | 6.07 | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| P/S Ratio, Competitors5 | ||||||||||||||||||||||||||
| Abbott Laboratories | 4.83 | 4.72 | 4.98 | 4.52 | 4.37 | 3.98 | 3.84 | 3.57 | 3.84 | 3.77 | 3.62 | 3.40 | 3.70 | 2.73 | 3.21 | 2.74 | 2.78 | — | — | — | ||||||
| AbbVie Inc. | 4.22 | 3.69 | 2.96 | 3.56 | 3.58 | 4.06 | 4.60 | 5.37 | 6.67 | 5.50 | 4.25 | 4.07 | 3.84 | 3.79 | 4.38 | 4.25 | 3.83 | — | — | — | ||||||
| Allergan PLC | 4.05 | 3.70 | 3.34 | 2.95 | 2.93 | 3.32 | 3.91 | 3.12 | 3.40 | 3.77 | 5.28 | 5.43 | 5.65 | 5.47 | 7.11 | 5.59 | 7.81 | — | — | — | ||||||
| Amgen Inc. | 6.03 | 5.61 | 5.00 | 4.78 | 5.22 | 5.56 | 5.65 | 5.27 | 5.82 | 5.85 | 5.85 | 5.48 | 5.65 | 5.01 | 5.97 | 5.60 | 5.28 | — | — | — | ||||||
| Biogen Inc. | 4.08 | 3.57 | 3.16 | 3.15 | 4.87 | 4.81 | 5.83 | 4.39 | 5.96 | 5.64 | 5.11 | 5.28 | 4.98 | 5.65 | 5.51 | 5.60 | 5.49 | — | — | — | ||||||
| Eli Lilly & Co. | 6.03 | 4.67 | 4.67 | 4.80 | 5.15 | 4.62 | 4.34 | 3.85 | 3.71 | 4.11 | 4.16 | 4.18 | 4.18 | 3.95 | 4.44 | 4.13 | 4.02 | — | — | — | ||||||
| Gilead Sciences Inc. | 4.00 | 3.76 | 3.69 | 3.84 | 3.84 | 4.17 | 4.43 | 3.52 | 4.10 | 3.54 | 3.42 | 3.05 | 3.08 | 3.13 | 3.32 | 3.48 | 3.80 | — | — | — | ||||||
| Johnson & Johnson | 4.79 | 4.16 | 4.32 | 4.62 | 4.45 | 4.61 | 4.36 | 4.29 | 4.56 | 5.06 | 4.93 | 4.60 | 4.62 | 4.37 | 4.78 | 4.49 | 4.13 | — | — | — | ||||||
| Merck & Co. Inc. | 4.33 | 4.59 | 4.87 | 4.67 | 4.92 | 4.57 | 4.29 | 3.75 | 3.68 | 3.80 | 4.25 | 4.34 | 4.54 | 4.15 | 4.41 | 3.80 | 3.56 | — | — | — | ||||||
| Pfizer Inc. | 3.66 | 3.85 | 3.80 | 4.20 | 4.49 | 4.75 | 4.51 | 3.89 | 4.05 | 4.00 | 3.80 | 3.75 | 3.84 | 3.82 | 4.08 | 3.95 | 3.76 | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | 5.34 | 4.79 | 4.56 | 5.11 | 6.62 | 6.08 | 6.92 | 5.20 | 5.92 | 8.09 | 9.56 | 9.27 | 7.86 | 7.61 | 9.82 | 8.95 | 9.38 | — | — | — | ||||||
| Vertex Pharmaceuticals Inc. | 14.95 | 13.89 | 13.34 | 13.54 | 15.54 | 14.96 | 17.14 | 16.47 | 16.42 | 16.47 | 18.23 | 14.60 | 12.51 | 11.33 | 15.62 | 15.73 | 20.38 | — | — | — | ||||||
| Zoetis Inc. | 11.00 | 9.37 | 9.57 | 8.35 | 7.03 | 7.92 | 7.88 | 7.10 | 7.18 | 6.40 | 5.85 | 5.83 | 5.31 | 4.95 | 5.21 | 4.87 | 4.42 | — | — | — | ||||||
Based on: 10-K (filing date: 2020-02-24), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28).
1 Data adjusted for splits and stock dividends.
2 Q4 2019 Calculation
Sales per share
= (RevenuesQ4 2019
+ RevenuesQ3 2019
+ RevenuesQ2 2019
+ RevenuesQ1 2019)
÷ No. shares of common stock outstanding
= (7,945,000,000 + 6,007,000,000 + 6,273,000,000 + 5,920,000,000)
÷ 2,257,510,796 = 11.58
3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Quarterly or Annual Report.
4 Q4 2019 Calculation
P/S ratio = Share price ÷ Sales per share
= 63.97 ÷ 11.58 = 5.52
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Bristol-Myers Squibb Co.’s P/S ratio increased from Q2 2019 to Q3 2019 and from Q3 2019 to Q4 2019. |
Price to Book Value (P/BV)
Bristol-Myers Squibb Co., historical P/BV calculation (quarterly data)
| Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 2,257,510,796 | 1,629,284,798 | 1,635,766,530 | 1,635,705,782 | 1,632,675,877 | 1,632,198,774 | 1,631,876,909 | 1,634,538,458 | 1,632,582,502 | 1,636,699,696 | 1,639,926,446 | 1,647,434,458 | 1,672,715,340 | 1,671,229,946 | 1,670,858,535 | 1,669,307,273 | 1,669,459,090 | 1,668,286,317 | 1,667,502,766 | 1,666,974,545 | ||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||
| Total Bristol-Myers Squibb Company shareholders’ equity (in millions) | 51,598 | 17,648 | 16,049 | 15,218 | 14,031 | 13,640 | 12,317 | 12,793 | 11,741 | 14,783 | 14,699 | 14,416 | 16,177 | 15,613 | 14,918 | 14,386 | 14,266 | 15,079 | 15,123 | 15,546 | ||||||
| Book value per share (BVPS)2 | 22.86 | 10.83 | 9.81 | 9.30 | 8.59 | 8.36 | 7.55 | 7.83 | 7.19 | 9.03 | 8.96 | 8.75 | 9.67 | 9.34 | 8.93 | 8.62 | 8.55 | 9.04 | 9.07 | 9.33 | ||||||
| Share price1, 3 | 63.97 | 57.37 | 45.40 | 45.64 | 50.65 | 49.21 | 57.92 | 52.04 | 63.87 | 60.95 | 54.24 | 55.67 | 54.78 | 51.96 | 74.66 | 72.26 | 60.20 | 66.80 | 68.24 | 64.54 | ||||||
| Valuation Ratio | ||||||||||||||||||||||||||
| P/BV ratio4 | 2.80 | 5.30 | 4.63 | 4.91 | 5.89 | 5.89 | 7.67 | 6.65 | 8.88 | 6.75 | 6.05 | 6.36 | 5.66 | 5.56 | 8.36 | 8.38 | 7.04 | 7.39 | 7.52 | 6.92 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | ||||||||||||||||||||||||||
| Abbott Laboratories | 4.96 | 4.65 | 4.86 | 4.49 | 4.38 | 3.94 | 3.72 | 3.23 | 3.40 | 2.95 | 2.71 | 2.42 | 3.76 | 2.72 | 3.20 | 2.70 | 2.68 | 3.19 | 3.27 | 3.17 | ||||||
| AbbVie Inc. | — | — | — | — | — | — | — | 44.74 | 36.95 | 22.43 | 18.89 | 21.33 | 21.24 | 14.80 | 19.21 | 21.77 | 22.17 | 21.56 | 20.64 | 75.48 | ||||||
| Allergan PLC | 1.12 | 1.00 | 0.88 | 0.75 | 0.71 | 0.76 | 0.89 | 0.69 | 0.73 | 0.82 | 1.06 | 1.07 | 1.08 | 0.82 | 1.28 | 1.15 | 1.54 | 1.53 | 1.74 | 1.66 | ||||||
| Amgen Inc. | 13.84 | 11.47 | 10.37 | 9.92 | 9.41 | 8.56 | 8.35 | 7.41 | 5.02 | 3.98 | 4.05 | 3.91 | 4.14 | 3.51 | 4.27 | 4.16 | 3.94 | 4.38 | 4.87 | 4.66 | ||||||
| Biogen Inc. | 4.40 | 3.63 | 3.44 | 3.15 | 5.03 | 4.63 | 6.13 | 3.94 | 5.80 | 5.19 | 5.16 | 5.30 | 4.70 | 5.32 | 5.43 | 5.93 | 6.31 | 5.83 | 5.61 | 8.10 | ||||||
| Eli Lilly & Co. | 51.67 | 31.28 | 39.03 | 46.37 | 12.87 | 8.58 | 8.96 | 6.18 | 7.33 | 6.20 | 6.49 | 6.43 | 6.33 | 5.28 | 6.25 | 5.55 | 5.51 | 5.94 | 6.39 | 5.35 | ||||||
| Gilead Sciences Inc. | 3.93 | 4.02 | 3.58 | 3.83 | 3.89 | 3.98 | 4.66 | 4.15 | 5.15 | 3.85 | 4.23 | 4.28 | 4.88 | 5.78 | 6.83 | 8.42 | 6.59 | 9.02 | 10.69 | 8.88 | ||||||
| Johnson & Johnson | 6.61 | 5.84 | 5.78 | 6.39 | 6.08 | 5.81 | 5.60 | 5.34 | 5.79 | 5.08 | 4.98 | 4.72 | 4.72 | 4.30 | 4.68 | 4.34 | 4.07 | 3.91 | 3.90 | 4.09 | ||||||
| Merck & Co. Inc. | 7.83 | 7.87 | 7.82 | 7.31 | 7.79 | 5.88 | 5.44 | 4.54 | 4.30 | 3.96 | 4.31 | 4.35 | 4.51 | 3.78 | 4.01 | 3.42 | 3.15 | 3.37 | 3.54 | 3.57 | ||||||
| Pfizer Inc. | 3.00 | 3.14 | 3.42 | 3.84 | 3.80 | 3.55 | 3.44 | 2.80 | 2.98 | 3.45 | 3.41 | 3.37 | 3.40 | 3.21 | 3.40 | 3.19 | 2.84 | 3.15 | 3.24 | 3.07 | ||||||
| Regeneron Pharmaceuticals Inc. | 3.79 | 3.48 | 3.38 | 3.74 | 5.07 | 4.92 | 5.97 | 4.80 | 5.66 | 7.37 | 9.07 | 9.49 | 8.58 | 8.02 | 11.19 | 10.54 | 10.53 | 17.80 | 18.04 | 16.29 | ||||||
| Vertex Pharmaceuticals Inc. | 10.23 | 9.57 | 9.09 | 9.36 | 10.68 | 14.56 | 16.73 | 16.56 | 20.14 | 21.11 | 23.25 | 19.64 | 18.42 | 18.42 | 24.79 | 21.23 | 22.38 | 33.24 | 38.35 | 31.53 | ||||||
| Zoetis Inc. | 25.42 | 21.53 | 24.00 | 21.31 | 18.74 | 21.38 | 22.36 | 19.72 | 21.52 | 16.49 | 17.11 | 17.96 | 17.46 | 15.25 | 18.64 | 20.16 | 19.72 | 18.42 | 20.48 | 17.82 | ||||||
Based on: 10-K (filing date: 2020-02-24), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28).
1 Data adjusted for splits and stock dividends.
2 Q4 2019 Calculation
BVPS = Total Bristol-Myers Squibb Company shareholders’ equity ÷ No. shares of common stock outstanding
= 51,598,000,000 ÷ 2,257,510,796 = 22.86
3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Quarterly or Annual Report.
4 Q4 2019 Calculation
P/BV ratio = Share price ÷ BVPS
= 63.97 ÷ 22.86 = 2.80
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. | Bristol-Myers Squibb Co.’s P/BV ratio increased from Q2 2019 to Q3 2019 but then decreased significantly from Q3 2019 to Q4 2019. |